行情

BIOC

BIOC

Biocept
NASDAQ

实时行情|Nasdaq Last Sale

0.2778
+0.0078
+2.89%
交易中 15:03 12/10 EST
开盘
0.2845
昨收
0.2700
最高
0.3000
最低
0.2700
成交量
968.92万
成交额
--
52周最高
3.720
52周最低
0.2401
市值
639.45万
市盈率(TTM)
-0.1042
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BIOC 新闻

  • The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
  • Benzinga.7小时前
  • The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
  • Benzinga.7小时前
  • Mid-Afternoon Market Update: Dow Falls 90 Points; XBiotech Shares Spike Higher
  • Benzinga.1天前
  • Mid-Day Market Update: Synthorx Jumps Following Acquisition News; Biocept Shares Plunge
  • Benzinga.1天前

更多

所属板块

医疗设备、用品及经销
+0.06%
医疗设备和用品
+0.14%

热门股票

名称
价格
涨跌幅

BIOC 简况

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.
展开

Webull提供Biocept Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。